Cover Image
Market Research Report

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016

Published by GlobalData Product code 339708
Published Content info 61 Pages
Immediate Delivery Available
Price
Back to Top
Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016
Published: November 30, 2016 Content info: 61 Pages
Description

GlobalData's clinical trial report, "Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016" provides an overview of Alpha- Antitrypsin Deficiency clinical trials scenario. This report provides top line data relating to the clinical trials on Alpha- Antitrypsin Deficiency. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
Product Code: GDHC3976CTIDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Alpha- Antitrypsin Deficiency
      • Dec 02, 2016: The Lancet Respiratory Medicine Publishes RAPID Extension Study Data on Effect of Zemaira [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency
      • Nov 14, 2016: Arrowhead Pharmaceuticals Presents New Data on ARC-AAT
      • Oct 20, 2016: Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
  • Source

List of Tables

  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Region, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Central and South America, Top Countries, 2016*
  • Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, G7 Countries (%), 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, E7 Countries (%), 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Alpha- Antitrypsin Deficiency Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016*
  • Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, G7 Countries (%), 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, E7 Countries (%), 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Alpha- Antitrypsin Deficiency Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Alpha- Antitrypsin Deficiency Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top